Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2025-04-25 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
CHANGE OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE
Board/Management Information Classification · 95% confidence The document is an announcement on the Hong Kong Stock Exchange regarding the appointment and resignation of a non-executive director and audit committee member. It concerns changes in the company's board composition, matching the definition of a board/management change announcement. Therefore, it is classified as Board/Management Information (MANG).
2025-04-25 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
Regulatory Filings Classification · 85% confidence The document is a monthly FF301 return submitted to the Hong Kong Exchanges and Clearing Limited under Chapter 19B of the Listing Rules, detailing movements in authorised capital, issued shares, share options, convertibles, and confirmations of compliance. It is a routine regulatory filing and does not fit into specific categories like annual/interim reports, earnings releases, or proxy materials. Therefore the best match is the general “Regulatory Filings” category (RNS).
2025-04-02 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
Annual Report Classification · 95% confidence The document is an announcement of annual results for the year ended 31 December 2024 by Immunotech Biopharm Ltd. It contains detailed financial highlights, business highlights, clinical trial updates, and management discussion and analysis. The content includes audited consolidated results, comparative figures, and substantive financial data for the full fiscal year. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or a certification. The presence of comprehensive financial data and business review aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K).
2025-03-31 English
VOLUNTARY ANNOUNCEMENT CONDITIONAL NEW DRUG APPLICATION OF EAL ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 87% confidence The document is a voluntary business update announcement by a Hong Kong–listed company regarding the acceptance of its new drug application (NDA) by the Chinese regulator. It does not contain financial results, a shareholder vote, dividend details, or a request for votes, nor does it change board composition, issue shares, or report earnings. It is not a full annual or interim report, nor a specialized regulatory submission like an audit or proxy statement. As it is a stand-alone company announcement that does not fit any more specific category, it falls under the general Regulatory Filings (RNS) classification.
2025-03-31 English
POSTPONEMENT OF BOARD MEETING
Regulatory Filings Classification · 80% confidence The document is a Hong Kong Exchange announcement notifying investors of the postponement of a scheduled board meeting. There are no actual changes in board composition or management (so not MANG), nor does it attach or publish financial results (so not RPA). It is a general regulatory announcement that does not fit a more specific category, and thus falls into the fallback Regulatory Filings category (RNS).
2025-03-24 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 85% confidence The document is a brief announcement by Immunotech Biopharm Ltd advising shareholders of the date on which its Board will meet to approve and publish the annual results for the year ended 31 December 2024. It does not contain financial results itself, but rather specifies the timing of the forthcoming report publication. This matches the definition of a Report Publication Announcement (RPA).
2025-03-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.